These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development. Boberg KM; Schrumpf E; Bergquist A; Broomé U; Pares A; Remotti H; Schjölberg A; Spurkland A; Clausen OP J Hepatol; 2000 Mar; 32(3):374-80. PubMed ID: 10735605 [TBL] [Abstract][Full Text] [Related]
3. Biliary dysplasia, cell proliferation and nuclear DNA-fragmentation in primary sclerosing cholangitis with and without cholangiocarcinoma. Bergquist A; Glaumann H; Stål P; Wang GS; Broomé U J Intern Med; 2001 Jan; 249(1):69-75. PubMed ID: 11168786 [TBL] [Abstract][Full Text] [Related]
4. p53 Protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis. Rizzi PM; Ryder SD; Portmann B; Ramage JK; Naoumov NV; Williams R Gut; 1996 Feb; 38(2):265-8. PubMed ID: 8801209 [TBL] [Abstract][Full Text] [Related]
5. K-ras mutations in the bile of patients with primary sclerosing cholangitis. Kubicka S; Kühnel F; Flemming P; Hain B; Kezmic N; Rudolph KL; Manns M; Meier PN Gut; 2001 Mar; 48(3):403-8. PubMed ID: 11171833 [TBL] [Abstract][Full Text] [Related]
6. Expression of p53 and PCNA in cholangiocarcinoma and primary sclerosing cholangitis. Batheja N; Suriawinata A; Saxena R; Ionescu G; Schwartz M; Thung SN Mod Pathol; 2000 Dec; 13(12):1265-8. PubMed ID: 11144921 [TBL] [Abstract][Full Text] [Related]
7. Primary Sclerosing Cholangitis-Associated Cholangiocarcinoma Demonstrates High Intertumor and Intratumor Heterogeneity. Kamp EJCA; Peppelenbosch MP; Doukas M; Verheij J; Ponsioen CY; van Marion R; Bruno MJ; Groot Koerkamp B; Dinjens WNM; de Vries AC Clin Transl Gastroenterol; 2021 Oct; 12(10):e00410. PubMed ID: 34608877 [TBL] [Abstract][Full Text] [Related]
8. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Isa T; Tomita S; Nakachi A; Miyazato H; Shimoji H; Kusano T; Muto Y; Furukawa M Hepatogastroenterology; 2002; 49(45):604-8. PubMed ID: 12063950 [TBL] [Abstract][Full Text] [Related]
9. Expression of p53 in adenocarcinoma of the gallbladder and bile ducts. Washington K; Gottfried MR Liver; 1996 Apr; 16(2):99-104. PubMed ID: 8740842 [TBL] [Abstract][Full Text] [Related]
10. Relation between K-ras codon 12 mutation and p53 protein overexpression in gallbladder cancer and biliary ductal epithelia in patients with pancreaticobiliary maljunction. Masuhara S; Kasuya K; Aoki T; Yoshimatsu A; Tsuchida A; Koyanagi Y J Hepatobiliary Pancreat Surg; 2000; 7(2):198-205. PubMed ID: 10982614 [TBL] [Abstract][Full Text] [Related]
11. Cholangiocarcinoma in young individuals with and without primary sclerosing cholangitis. Björnsson E; Angulo P Am J Gastroenterol; 2007 Aug; 102(8):1677-82. PubMed ID: 17433022 [TBL] [Abstract][Full Text] [Related]
12. Low frequency of p53 and ras mutations in bile of patients with hepato-biliary disease: a prospective study in more than 100 patients. Müller P; Ostwald C; Püschel K; Brinkmann B; Plath F; Kröger J; Barten M; Nizze H; Schareck WD; Hauenstein K; Liebe S; Löhr JM Eur J Clin Invest; 2001 Mar; 31(3):240-7. PubMed ID: 11264652 [TBL] [Abstract][Full Text] [Related]
13. Next-generation sequencing mutation analysis on biliary brush cytology for differentiation of benign and malignant strictures in primary sclerosing cholangitis. Kamp EJCA; Dinjens WNM; van Velthuysen MF; de Jonge PJF; Bruno MJ; Peppelenbosch MP; de Vries AC Gastrointest Endosc; 2023 Mar; 97(3):456-465.e6. PubMed ID: 36252869 [TBL] [Abstract][Full Text] [Related]
14. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Bergquist A; Glaumann H; Persson B; Broomé U Hepatology; 1998 Feb; 27(2):311-6. PubMed ID: 9462625 [TBL] [Abstract][Full Text] [Related]
16. K-ras codon 12 and p53 mutations in biopsy specimens and bile from biliary tract cancers. Itoi T; Takei K; Shinohara Y; Takeda K; Nakamura K; Horibe T; Sanada A; Ohno H; Matsubayashi H; Saito T; Watanabe H Pathol Int; 1999 Jan; 49(1):30-7. PubMed ID: 10227722 [TBL] [Abstract][Full Text] [Related]
17. p53 gene mutation and p53 protein overexpression in a patient with simultaneous double cancer of the gallbladder and bile duct associated with pancreaticobiliary maljunction. Kasuya K; Nagakawa Y; Matsudo T; Ozawa T; Tsuchida A; Aoki T; Itoi T; Itokawa F J Hepatobiliary Pancreat Surg; 2009; 16(3):376-81. PubMed ID: 19183832 [TBL] [Abstract][Full Text] [Related]
18. The Role of K-Ras and P53 in Biliary Tract Carcinoma. Ahmad S; Badr B; Khan A; Rehman R; Ghias K; Muhammad JS; Khan MR J Pak Med Assoc; 2021 Oct; 71(10):2378-2384. PubMed ID: 34974575 [TBL] [Abstract][Full Text] [Related]
19. Two distinct pathways of carcinogenesis in primary sclerosing cholangitis. Zen Y; Quaglia A; Heaton N; Rela M; Portmann B Histopathology; 2011 Dec; 59(6):1100-10. PubMed ID: 22175890 [TBL] [Abstract][Full Text] [Related]
20. Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma. Furubo S; Harada K; Shimonishi T; Katayanagi K; Tsui W; Nakanuma Y Histopathology; 1999 Sep; 35(3):230-40. PubMed ID: 10469215 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]